Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
14 Dezember 2023 - 12:30PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced the appointment of Christi Shaw to the company’s board of
directors.
“Christi is an inspiring leader who knows firsthand what it
takes to transform cutting-edge science into practice-changing
commercial treatment options, most recently building and scaling
the industry’s premier autologous cell therapy company as CEO of
Kite,” said John Evans, chief executive officer of Beam
Therapeutics. “Her experience leading the transformation of novel
science into approved medicines, coupled with her unwavering
dedication and drive to serve people living with life-threatening
diseases, make her an ideal fit for Beam as we look to advance our
pipeline of novel base editing therapeutics.”
Ms. Shaw has more than 30 years of experience in the
biopharmaceutical industry, and most recently served as chief
executive officer of Kite, a Gilead company specializing in the
development of immuno-oncology therapies until March 2023. Prior to
Kite, Ms. Shaw served as an executive officer of Eli Lilly and
Company (Lilly), a global healthcare company, and president of
Lilly Bio-Medicines, the business within Lilly that comprises
neuroscience and immunology. Before Lilly, she served as U.S.
country head and president of Novartis Pharmaceutical Corporation,
a global healthcare company, and in a prior role, as North American
region head of Novartis Oncology. Ms. Shaw also held several
leadership positions at Johnson & Johnson. She serves as a
member of the board of directors of Avantor and is the co-founder
of the More Moments More Memories Foundation, which helps people
access oncology clinical trials for potentially life-saving
treatment. She holds a bachelor’s degree in business administration
from Iowa State University and an MBA from the University of
Wisconsin.
“Beam is pioneering the next wave of innovation in genetic
medicine and gene editing and is on the cusp of significant
clinical milestones across its impressive portfolio,” said Ms.
Shaw. “Base editing has the potential to transform treatment for
many people suffering from serious and devastating diseases, and
Beam’s integrated platform, development and manufacturing
capabilities are a critical differentiator for the company. I look
forward to working alongside such a high-caliber organization and
team as we work to bring these innovative therapies to
patients.”
About Beam TherapeuticsBeam Therapeutics
(Nasdaq: BEAM) is a biotechnology company committed to establishing
the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform
that includes a suite of gene editing and delivery technologies and
is in the process of building internal manufacturing capabilities.
Beam’s suite of gene editing technologies is anchored by base
editing, a proprietary technology that is designed to enable
precise, predictable and efficient single base changes, at targeted
genomic sequences, without making double-stranded breaks in the
DNA. This has the potential to enable a wide range of potential
therapeutic editing strategies that Beam is using to advance a
diversified portfolio of base editing programs. Beam is a
values-driven organization committed to its people, cutting-edge
science, and a vision of providing life-long cures to patients
suffering from serious diseases.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned not to place undue
reliance on these forward-looking statements, including, but not
limited to, statements related to: the therapeutic applications and
potential of our technology, including our ability to develop
life-long, curative, precision genetic medicines for patients
through base editing. Each forward-looking statement is subject to
important risks and uncertainties that could cause actual results
to differ materially from those expressed or implied in such
statement, including, without limitation, risks and uncertainties
related to: our ability to successfully achieve the benefits of our
portfolio prioritization and strategic restructuring, including our
ability to seek, establish and maintain partners for certain of our
programs; our ability to develop, obtain regulatory approval for,
and commercialize our product candidates, which may take longer or
cost more than planned; our ability to raise additional funding,
which may not be available; our ability to obtain, maintain and
enforce patent and other intellectual property protection for our
product candidates; the potential impact of pandemics and other
health emergencies, including their impact on the global supply
chain; the uncertainty that our product candidates will receive
regulatory approval necessary to initiate human clinical studies;
that preclinical testing of our product candidates and preliminary
or interim data from preclinical studies and clinical trials may
not be predictive of the results or success of ongoing or later
clinical trials; that initiation and enrollment of, and anticipated
timing to advance, our clinical trials may take longer than
expected; that our product candidates may experience manufacturing
or supply interruptions or failures; risks related to competitive
products; and the other risks and uncertainties identified under
the headings “Risk Factors Summary” and “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2022,
our Quarterly Report on Form 10-Q for the quarter ended March 31,
2023, our Quarterly Report on Form 10-Q for the quarter ended June
30, 2023, our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023, and in any subsequent filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release. Factors
or events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by applicable
law.
Contacts: Investors:Holly ManningTHRUST
Strategic Communicationsholly@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024